Have a personal or library account? Click to login
Prevalence and Drug Resistance Pattern of Mycobacterium tuberculosis Isolated from Tuberculosis Patients in Basra, Iraq Cover

Prevalence and Drug Resistance Pattern of Mycobacterium tuberculosis Isolated from Tuberculosis Patients in Basra, Iraq

Open Access
|May 2022

References

  1. Ahmed ST. Molecular investigation and genotyping of pulmonary Mycobacterium tuberculosis strains in Iraq [PhD Thesis]. Baghdad (Iraq): University of Baghdad, College of Science for Women; 2018.
  2. Al-Khafaji J. Characterization of Mycobacterium tuberculosis and predisposition factors association with tuberculosis among risk population in Baghdad city. JUBPAS. 2014;22(9):2547–2558.
  3. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, Mehta A. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis. 2003;36(12):e152–e154. https://doi.org/10.1086/374931
  4. Al-Rubayai DS. Molecular detection of specific gene mutations associated with isoniazid or rifampicin resistance among category II pulmonary tuberculosis using DNA microarray [PhD Thesis]. Baghdad (Iraq): Al-Nahrain University, College of Medicine; 2011.
  5. Bedewi SG. Assessment of the resistance of the Mycobacterium tuberculosis to antibiotics and investigation the associated bacteria in patients [Master Thesis]. Baghdad (Iraq): University of Baghdad, College of Science for Women; 2011.
  6. Central Statistical Organization. Baghdad (Iraq): Ministry of Planning, Republic of Iraq; 2019. Available from http://cosit.gov.iq/ar/2018-2019
  7. Chonde TM, Basra D, Mfinanga SG, Range N, Lwilla F, Shirima RP, van Deun A, Zignol M, Cobelens FG, Egwaga SM, et al. National anti-tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis. 2010;14(8):967–972.
  8. Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, Köser CU, Gonzalez-Angulo LY, Tosas-Auget O, Ismail N, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008. https://doi.org/10.1371/journal.pmed.1003008
  9. Diefenbach-Elstob T, Graves P, Dowi R, Gula B, Plummer D, McBryde E, Pelowa D, Siba P, Pomat W, Warner J. The epidemio­ logy of tuberculosis in the rural Balimo region of Papua New Guinea. Trop Med Int Health. 2018;23(9):1022–1032. https://doi.org/10.1111/tmi.13118
  10. Dogar OF, Shah SK, Chughtai AA, Qadeer E. Gender disparity in tuberculosis cases in eastern and western provinces of Pakistan. BMC Infect Dis. 2012;12:244. https://doi.org/10.1186/1471-2334-12-244
  11. Durib AK, Blinova EV. Tuberculosis in Baghdad, Iraq 2012–2016: Retrospective study. Med Leg Update. 2020;20(4):1311–1314. https://doi.org/10.37506/mlu.v20i4.2010
  12. Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, Tessema B, Moges F. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):219. https://doi.org/10.1186/s12879-017-2323-y
  13. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2): 158–163. https://doi.org/10.1136/thx.2005.045963
  14. Godreuil S, Tazi L, Bañuls AL. Pulmonary tuberculosis and Mycobacterium tuberculosis: modern molecular epidemiology and perspectives. In: Tibayrenc M, editor. Encyclopedia of infectious diseases. Hoboken (USA): John Wiley and Sons; 2007. p. 1–29.
  15. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72(9):1761–1768.
  16. Hajissa K, Marzan M, Idriss MI, Islam MA. Prevalence of drug-resistant tuberculosis in Sudan: a systematic review and meta-analysis. Antibiotics (Basel). 2021 Jul 31;10(8):932. https://doi.org/10.3390/antibiotics10080932
  17. He XC, Zhang XX, Zhao JN, Liu Y, Yu CB, Yang GR, Li HC. Epidemiological trends of drug-resistant tuberculosis in China from 2007 to 2014: a retrospective study. Medicine (Baltimore). 2016; 95(15):e3336. https://doi.org/10.1097/MD.0000000000003336
  18. Hernandez-Romieu AC, Little BP, Bernheim A, Schechter MC, Ray SM, Bizune D, Kempker R. Increasing number and volume of cavitary lesions on chest computed tomography are associated with prolonged time to culture conversion in pulmonary tuberculosis. Open Forum Infect Dis. 2019;6(6):ofz232. https://doi.org/10.1093/ofid/ofz232
  19. Jappar SB, Low SY. Tuberculosis trends over a five-year period at a tertiary care university-affiliated hospital in Singapore. Singapore Med J. 2015;56(9):502–505. https://doi.org/10.11622/smedj.2015134
  20. Jimma W, Ghazisaeedi M, Shahmoradi L, Abdurahman AA, Kalhori SRN, Nasehi M, Yazdi S, Safdari R. Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta-analysis. Rev Soc Bras Med Trop. 2017;50(3):287–295. https://doi.org/10.1590/0037-8682-0002-2017
  21. Kapata N, Chanda-Kapata P, Ngosa W, Metitiri M, Klinkenberg E, Kalisvaart N, Sunkutu V, Shibemba A, Chabala C, Chongwe G, et al. The prevalence of tuberculosis in Zambia: results from the first national TB prevalence survey. 2013–2014. PLoS One. 2016; 11(1):e0146392. https://doi.org/10.1371/journal.pone.0146392
  22. Karadakhy K, Othman N, Ibrahimm F, Saeed AA, Amin AAH. Tuberculosis in Sulaimaniyah, Iraqi Kurdistan: a detailed analysis of cases registered in treatment centers. Tanaffos. 2016;15(4):197–204.
  23. Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, Vashakidze S. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012;54(6):e51–e54. https://doi.org/10.1093/cid/cir904
  24. Khdban MM. Isolation and identification of M. tuberculosis and detection of polymorphism in multidrug resistance gene [Master Thesis]. Baqubah (Iraq): Diyala University, College of Science; 2018.
  25. Lan Y, Li Y, Chen L, Zhang J, Zhang H. Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China. Infect Drug Resist. 2019;12:211–219. https://doi.org/10.2147/IDR.S188538
  26. Liu JJ, Yao HY, Liu EY. Analysis of factors affecting the epidemiology of tuberculosis in China. Int J Tuberc Lung Dis. 2005;9(4):450–454.
  27. Lohiya A, Suliankatchi Abdulkader R, Rath RS, Jacob O, Chinnakali P, Goel AD, Agrawal S. Prevalence and patterns of drug resistant pulmonary tuberculosis in India – a systematic review and meta-analysis. J Glob Antimicrob Resist. 2020;22:308–316. https://doi.org/10.1016/j.jgar.2020.03.008
  28. Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM, Salakaia A. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis. 2009;13(1):68–73.
  29. Madrazo-Moya CF, Cancino-Muñoz I, Cuevas-Córdoba B, González-Covarrubias V, Barbosa-Amezcua M, Soberón X, Muñiz-Salazar R, Martínez-Guarneros A, Bäcker C, Zarrabal-Meza J, et al. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. PLoS One. 2019;14(6):e0213046. https://doi.org/10.1371/journal.pone.0213046
  30. Mankhi AA. Manual of laboratory guideline in the national reference laboratory in Iraq (2nd Edition). Baghdad (Iraq): Ministry of Health, Chest and Respiratory Diseases Center in collaboration with WHO; 2009.
  31. Merza MA, Farnia P, Salih AM, Masjedi MR, Velayati AA. First insight into the drug resistance pattern of Mycobacterium tuberculosis in Dohuk, Iraq: using spoligotyping and MIRU-VNTR to characterize multidrug resistant strains. J Infect Public Health. 2011; 4(1):41–47. https://doi.org/10.1016/j.jiph.2010.11.002
  32. Merza MA. A 5-year experience characterizing the demographic and clinical profile and directly observed treatment short-course treatment outcome in National Tuberculosis Center of Duhok province, Iraqi Kurdistan. SAGE Open Med. 2020;8:2050312120921055. https://doi.org/10.1177/2050312120921055
  33. Mokdad AH, Jaber S, Aziz MI, AlBuhairan F, AlGhaithi A, AlHamad NM, Al-Hooti SN, Al-Jasari A, AlMazroa MA, AlQasmi AM, et al. The state of health in the Arab world, 1990– 2010: an analysis of the burden of diseases, injuries, and risk factors. Lancet. 2014;383(9914):309–320. https://doi.org/10.1016/S0140-6736(13)62189-3
  34. Nistal-Nuño B. Joinpoint regression analysis to evaluate traffic public health policies by national temporal trends from 2000 to 2015. Int J Inj Contr Saf Promot. 2018;25(2):128–133. https://doi.org/10.1080/17457300.2017.1341937
  35. Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, et al. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran – eight years of surveillance. Int J Infect Dis. 2009;13(5):e236–e240. https://doi.org/10.1016/j.ijid.2008.11.027
  36. Song WM, Li YF, Ma XB, Liu JY, Tao NN, Liu Y, Zhang QY, Xu TT, Li SJ, Yu CB, et al. Primary drug resistance of Mycobacterium tuberculosis in Shandong, China, 2004–2018. Respir Res. 2019;20(1):223. https://doi.org/10.1186/s12931-019-1199-3
  37. Sousa J, Cá B, Maceiras AR, Simões-Costa L, Fonseca KL, Fernandes AI, Ramos A, Carvalho T, Barros L, Magalhães C, et al. Mycobacterium tuberculosis associated with severe tuberculosis evades cytosolic surveillance systems and modulates IL-1β production. Nat Commun. 2020;11(1):1949. https://doi.org/10.1038/s41467-020-15832-6
  38. Urassa W, Mugusi F, Villamor E, Msamanga G, Moshiro C, Bosch R, Saathoff E, Fawzi W. Primary antimicrobial resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative patients in Dar es Salaam Tanzania. BMC Res Notes. 2008;1:58. https://doi.org/10.1186/1756-0500-1-58
  39. WHO. Global tuberculosis report 2017. Geneva (Switzerland): World Health Organization; 2017. Available from https://apps.who.int/iris/bitstream/handle/10665/ 259366/9789241565516-eng.pdf?sequence=1
  40. WHO. Global tuberculosis report 2018. Geneva (Switzerland): World Health Organization; 2018. Available from https://apps.who. int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf
  41. WHO. Global tuberculosis report 2019. Geneva (Switzerland): World Health Organization; 2019. Available from https://apps.who.int/iris/rest/bitstreams/1257851/retrieve
  42. WHO. Global tuberculosis report 2020. Geneva (Switzerland): World Health Organization; 2020. Available from https://apps.who.int/iris/rest/bitstreams/1312164/retrieve
  43. WHO. Tuberculosis control in the Eastern Mediterrean Region: progress report. 2009; https://apps.who.int/iris/handle/10665/116621
  44. WHO. WHO annual report on global TB control – summary. Wkly Epidemiol Rec. 2003;78(15):122–128. Available from https://apps.who.int/iris/handle/10665/232138
  45. Yang Y, Zhou C, Shi L, Meng H, Yan H. Prevalence and characterization of drug-resistant tuberculosis in a local hospital of Northeast China. Int J Infect Dis. 2014;22:83–86. https://doi.org/10.1016/j.ijid.2013.12.015
DOI: https://doi.org/10.33073/pjm-2022-018 | Journal eISSN: 2544-4646 | Journal ISSN: 1733-1331
Language: English
Page range: 205 - 215
Submitted on: Jan 17, 2022
Accepted on: Mar 12, 2022
Published on: May 31, 2022
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Khairallah A.S. Mohammed, Ghorob S. Khudhair, Dheyaa Bekheet Al-Rabeai, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.